2015
Frequency and Effects of Excess Dosing of Anticoagulants in Patients ≤55 Years With Acute Myocardial Infarction Who Underwent Percutaneous Coronary Intervention (from the VIRGO Study)
Gupta A, Chui P, Zhou S, Spertus JA, Geda M, Lorenze N, Lee I, Onofrio G, Lichtman JH, Alexander KP, Krumholz HM, Curtis JP. Frequency and Effects of Excess Dosing of Anticoagulants in Patients ≤55 Years With Acute Myocardial Infarction Who Underwent Percutaneous Coronary Intervention (from the VIRGO Study). The American Journal Of Cardiology 2015, 116: 1-7. PMID: 25937348, PMCID: PMC4466069, DOI: 10.1016/j.amjcard.2015.03.032.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge DistributionAngioplasty, Balloon, CoronaryAnticoagulantsAntithrombinsBody Mass IndexCohort StudiesFemaleHemorrhageHeparinHirudinsHumansMaleMiddle AgedMyocardial InfarctionPeptide FragmentsPercutaneous Coronary InterventionPlatelet Glycoprotein GPIIb-IIIa ComplexPrevalenceRecombinant ProteinsRisk AssessmentRisk FactorsSex DistributionTreatment OutcomeUnited StatesConceptsPercutaneous coronary interventionGlycoprotein IIb/IIIa inhibitorsIIb/IIIa inhibitorsExcess dosingAcute myocardial infarctionCoronary interventionMultivariable analysisMyocardial infarctionUnderwent Percutaneous Coronary InterventionLower body weightOlder patientsYounger patientsUnfractionated heparinMedical recordsUnivariate analysisAnticoagulant agentsAnticoagulant drugsBody weightPatientsDosingYounger ageLogistic regressionYoung womenAnticoagulantsGender-based differences
2004
Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3)
Curtis JP, Alexander JH, Huang Y, Wallentin L, Verheugt FW, Armstrong PW, Krumholz HM, Van de Werf F, Danays T, Cheeks M, Granger CB, Investigators A. Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3). The American Journal Of Cardiology 2004, 94: 279-283. PMID: 15276088, DOI: 10.1016/j.amjcard.2004.04.019.Peer-Reviewed Original ResearchMeSH KeywordsAgedConfidence IntervalsDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationElectrocardiographyFemaleFollow-Up StudiesHeparin, Low-Molecular-WeightHumansIncidenceIntracranial HemorrhagesMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionMyocardial IschemiaPartial Thromboplastin TimeProbabilityRandomized Controlled Trials as TopicRisk AssessmentSeverity of Illness IndexSurvival RateTenecteplaseThrombolytic TherapyTissue Plasminogen ActivatorTreatment OutcomeConceptsWeight-adjusted heparinST-elevation myocardial infarctionASSENT-3Myocardial infarctionASSENT-2Major bleedingIntracranial hemorrhageSmall doseFull-dose tenecteplaseLess major bleedingNew thrombolytic regimenOutcomes of patientsAcute myocardial infarctionPartial thromboplastin timeSimilar ratesRefractory ischemiaThrombolytic regimenRecurrent infarctionBaseline characteristicsHemorrhagic complicationsUnfractionated heparinThromboplastin timePatientsInfarctionTenecteplase